A collaboration between the NIAID, GSK and Sanofi Pasteur is hoping to show that their combination vaccine HVTN 702 is effective in a new Phase 2b/3 trial that kicked off this week in South Africa.
Despite numerous set backs over the years there is still intense interest in preventative HIV vaccines. Specially modified to better attack the variant of the virus found in the region around South Africa, the NIH/GSK/Sanofi Pasteur investigators are hoping to build on the progress seen previously in trials undertaken in Thailand.
Results from the trial are expected in 2020 so only time will tell if this vaccine represents a major step forward in eradicating HIV.
“Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa,” Fauci said.